For the quarter ending 2026-03-31, PCRX had -$14,239K decrease in cash & cash equivalents over the period. $22,956K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Amortization of debt issuance costs | - | - | 626 | 1,694 |
| Amortization of debt discount | - | - | 56 | 45 |
| Loss (gain) on early extinguishment of debt | - | 0 | -983 | 0 |
| Net income | 2,916 | 1,637 | 5,432 | -35 |
| Goodwill impairment | - | 0 | 0 | - |
| Indefinite-lived intangible asset impairment | - | 0 | 25,866 | - |
| Investment impairment | - | 0 | 0 | 11,000 |
| Loss on lease terminations | - | 0 | - | - |
| Deferred taxes | 1,730 | -3,744 | 8,072 | 2,149 |
| Depreciation of fixed assets and amortization of intangible assets | 21,331 | 21,342 | 21,191 | 48,490 |
| Amortization of debt issuance costs and debt discount | 577 | 2,997 | - | - |
| Stock-based compensation | 13,539 | 13,499 | 13,978 | 30,025 |
| Changes in contingent consideration | -2,277 | 232 | 625 | -3,032 |
| Net accretion of discount on available-for-sale investments | 570 | 4,927 | - | - |
| Other net gains | 0 | 367 | 0 | -5,887 |
| Accounts receivable, net | 1,567 | 8,799 | 897 | 1,046 |
| Inventories, net | -2,491 | -4,817 | 9,513 | 22,871 |
| Prepaid expenses and other assets | 4,537 | -12,699 | -4,724 | 18,635 |
| Accounts payable | -936 | -2,929 | -12,013 | 9,344 |
| Accrued expenses | -3,160 | - | 7,530 | -14,675 |
| Accrued expenses and other liabilities | - | 6,853 | - | - |
| Other liabilities | -1,791 | - | -5,826 | 10,905 |
| Purchases of debt and equity investments | - | 0 | 0 | 1,250 |
| Net cash provided by operating activities | 25,680 | 43,689 | 60,834 | 47,471 |
| Acquisition of gq bio therapeutics gmbh (net of cash acquired) | 335 | 0 | 0 | 16,702 |
| Purchases of fixed assets | 2,724 | 218 | 3,870 | 11,245 |
| Purchases of available-for-sale investments | 0 | 27,591 | 38,765 | 74,685 |
| Sales of available-for-sale investments | 22,500 | 47,142 | 86,249 | 140,416 |
| Net cash provided by (used in) investing activities | 19,441 | 19,333 | 43,614 | 36,534 |
| Repayment of term loan facility-Term Loan BFacility | - | 0 | - | - |
| Repayment of term loan facility-Term Loan AFacility | - | 0 | 98,749 | 6,563 |
| Purchase of capped call transactions | - | 0 | 0 | 0 |
| Repayments of convertible senior notes-Convertible Senior Notes Due2025 | - | 0 | 202,487 | 0 |
| Proceeds from revolving credit facility | - | 0 | 101,000 | - |
| Proceeds from term loan a facility | - | 0 | - | - |
| Debt extinguishment costs | - | 0 | - | - |
| Repayments of convertible senior notes-Convertible Senior Notes Due2024 | - | 0 | 0 | 0 |
| Payment of debt issuance and financing costs | - | -17 | 2,203 | 0 |
| Proceeds from exercises of stock options | 2 | 490 | 12 | - |
| Proceeds from 2029 convertible senior notes | - | 0 | 0 | 0 |
| Proceeds from shares issued under employee stock purchase plan | - | 1,232 | 0 | 1,569 |
| Payment of employee withholding taxes on restricted stock unit vests | 4,355 | 143 | 8 | 5,466 |
| Purchase of treasury stock, inclusive of broker fees | 50,045 | 48,248 | 50,041 | 50,039 |
| Repayment of term loan a facility | 0 | - | - | - |
| Repayment of revolving credit facility | 5,000 | 5,000 | 5,000 | - |
| Net cash used in financing activities | -59,398 | -51,652 | -257,476 | -60,499 |
| Effect of exchange rate changes on cash and cash equivalents | 38 | -414 | 133 | 204 |
| Net (decrease) increase in cash and cash equivalents | -14,239 | 10,956 | -152,895 | 23,710 |
| Cash and cash equivalents, beginning of period | 158,545 | 147,589 | 276,774 | - |
| Cash and cash equivalents, end of period | 144,306 | 158,545 | 147,589 | - |
Pacira BioSciences, Inc. (PCRX)
Pacira BioSciences, Inc. (PCRX)